Journal of Oral Medicine and Pain

  • 제47권1호
  • /
  • Pages.1-9
  • /
  • 2022
  • /
  • 2288-9272(pISSN)
  • /
  • 2383-8493(eISSN)
대한안면통증구강내과학회 (Korean Academy of Orofacial Pain and Oral Medicine)
권호 표지
DOI QR코드

DOI QR Code

Medication-Related Osteonecrosis of the Jaws: A Literature Review

  • Kim, Gyeong-Mi (Department of Oral and Maxillofacial Surgery, College of Dentistry, Chosun University) ;
  • Moon, Seong-Yong (Department of Oral and Maxillofacial Surgery, College of Dentistry, Chosun University) ;
  • You, Jae-Seek (Department of Oral and Maxillofacial Surgery, College of Dentistry, Chosun University) ;
  • Kim, Gyeong-Yun (Department of Oral and Maxillofacial Surgery, College of Dentistry, Chosun University) ;
  • Oh, Ji-Su (Department of Oral and Maxillofacial Surgery, College of Dentistry, Chosun University)
  • 투고 : 2022.03.02
  • 심사 : 2022.03.22
  • 발행 : 2022.03.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Medication-related osteonecrosis of the jaw (MRONJ) is a serious side effect of antiresorptive agents and bone-modifying agents. It is of the utmost importance to know the management of the MRONJ to improve the patient's quality of life. This study comprehensively reviews the current definitions of MRONJs, and antiresorptive medications, clinical manifestation and staging, risk factors, treatment strategies, and prevention methods of MRONJ. The disease is defined as an exposure of bone and osteonecrosis of the jaw in the oral cavity for at least 8 weeks in patients taking antiresorptive drugs or antiangiogenic agents and with no history of radiotherapy treatment of the jaws. Many articles have reported risk factors associated with MRONJ such as systemic diseases, antiresorptive medication, oral infection, and poor oral hygiene. Osteonecrosis and antiresorptive medications including bisphosphonate and denosumab have been strongly associated, but the pathology of MRONJ is only limited. Hence, an effective and appropriate management and treatment for MRONJ is still to be defined. The objectives of MRONJ treatment are to minimize osteonecrosis and relieve symptoms, and many treatments are suggested from conservative treatment to marginal resection, but this remains controversial. Appropriate treatment of MRONJ remained difficult, although many studies are being covered.

키워드

참고문헌

  1. Kawahara M, Kuroshima S, Sawase T. Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review. Int J Implant Dent 2021;7:47. https://doi.org/10.1186/s40729-021-00323-0
  2. Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medicationrelated osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014;72:1938-1956. Erratum in: J Oral Maxillofac Surg 2015;73:1440. Erratum in: J Oral Maxillofac Surg 2015;73:1879. https://doi.org/10.1016/j.joms.2014.04.031
  3. Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 2015;30:3-23. https://doi.org/10.1002/jbmr.2405
  4. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-1117. https://doi.org/10.1016/S0278-2391(03)00720-1
  5. Aghaloo TL, Felsenfeld AL, Tetradis S. Osteonecrosis of the jaw in a patient on Denosumab. J Oral Maxillofac Surg 2010;68:959-963. https://doi.org/10.1016/j.joms.2009.10.010
  6. Taylor KH, Middlefell LS, Mizen KD. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg 2010;48:221-223. https://doi.org/10.1016/j.bjoms.2009.08.030
  7. Kim JW, Kwak MK, Han JJ, et al. Medication related osteonecrosis of the jaw: 2021 position statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons. J Bone Metab 2021;28:279-296. https://doi.org/10.11005/jbm.2021.28.4.279
  8. Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' position paper on medication-related osteonecrosis of the jaw-2022 update. J Oral Maxillofac Surg 2022. doi: 10.1016/j.joms.2022.02.008. [Epub ahead of print]
  9. Miksad RA, Lai KC, Dodson TB, et al. Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. Oncologist 2011;16:121-132. https://doi.org/10.1634/theoncologist.2010-0183
  10. Lerman MA, Xie W, Treister NS, Richardson PG, Weller EA, Woo SB. Conservative management of bisphosphonate-related osteonecrosis of the jaws: staging and treatment outcomes. Oral Oncol 2013;49:977-983. https://doi.org/10.1016/j.oraloncology.2013.05.012
  11. Voss PJ, Poxleitner P, Schmelzeisen R, Stricker A, Semper-Hogg W. Update MRONJ and perspectives of its treatment. J Stomatol Oral Maxillofac Surg 2017;118:232-235. https://doi.org/10.1016/j.jormas.2017.06.012
  12. Shibahara T. Antiresorptive agent-related osteonecrosis of the jaw (ARONJ): a twist of fate in the bone. Tohoku J Exp Med 2019;247:75-86. https://doi.org/10.1620/tjem.247.75
  13. Lombard T, Neirinckx V, Rogister B, Gilon Y, Wislet S. Medication-related osteonecrosis of the jaw: new insights into molecular mechanisms and cellular therapeutic approaches. Stem Cells Int 2016;2016:8768162. https://doi.org/10.1155/2016/8768162
  14. Goodchild JH, Donaldson M. What do you really need to know about bisphosphonates? Gen Dent 2018;66:23-26.
  15. Favia G, Tempesta A, Limongelli L, Crincoli V, Maiorano E. Medication-related osteonecrosis of the jaw: surgical or non-surgical treatment? Oral Dis 2018;24:238-242. https://doi.org/10.1111/odi.12764
  16. Kim HW, Lee MW, Lee JH, Kim MY. Comparison of the effect of oral versus intravenous bisphosphonate administration on osteoclastogenesis in advanced-stage medication-related osteonecrosis of the jaw patients. J Clin Med 2021;10:2988. https://doi.org/10.3390/jcm10132988
  17. Khan AA, Rios LP, Sandor GK, et al. Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons. J Rheumatol 2011;38:1396-1402. https://doi.org/10.3899/jrheum.100221
  18. Ulmner M, Jarnbring F, Torring O. Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate. J Oral Maxillofac Surg 2014;72:76-82. https://doi.org/10.1016/j.joms.2013.06.221
  19. Lo JC, O'Ryan FS, Gordon NP, et al. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 2010;68:243-253. https://doi.org/10.1016/j.joms.2009.03.050
  20. Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 2017;377:1417-1427. https://doi.org/10.1056/NEJMoa1708322
  21. Yarom N, Shapiro CL, Peterson DE, et al. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline. J Clin Oncol 2019;37:2270-2290. https://doi.org/10.1200/jco.19.01186
  22. Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): initial discovery and subsequent development. J Oral Maxillofac Surg 2009;67(5 Suppl):13-18. https://doi.org/10.1016/j.joms.2008.10.005
  23. He L, Sun X, Liu Z, Qiu Y, Niu Y. Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw. Int J Oral Sci 2020;12:30. https://doi.org/10.1038/s41368-020-00093-2
  24. Di Fede O, Panzarella V, Mauceri R, et al. The dental management of patients at risk of medication-related osteonecrosis of the jaw: new paradigm of primary prevention. Biomed Res Int 2018;2018:2684924. https://doi.org/10.1155/2018/2684924
  25. Walton K, Grogan TR, Eshaghzadeh E, et al. Medication related osteonecrosis of the jaw in osteoporotic vs oncologic patients-quantifying radiographic appearance and relationship to clinical findings. Dentomaxillofac Radiol 2019;48:20180128. https://doi.org/10.1259/dmfr.20180128
  26. McGowan K, McGowan T, Ivanovski S. Risk factors for medication-related osteonecrosis of the jaws: a systematic review. Oral Dis 2018;24:527-536. https://doi.org/10.1111/odi.12708
  27. Khan AA, Morrison A, Kendler DL, et al. Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the international task force on ONJ. J Clin Densitom 2017;20:8-24. https://doi.org/10.1016/j.jocd.2016.09.005
  28. Kuroshima S, Sasaki M, Murata H, Sawase T. Medication-related osteonecrosis of the jaw-like lesions in rodents: a comprehensive systematic review and meta-analysis. Gerodontology 2019;36:313-324. https://doi.org/10.1111/ger.12416
  29. Japanese Allied Committee on Osteonecrosis of the Jaw, Yoneda T, Hagino H, et al. Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab 2017;35:6-19. Erratum in: J Bone Miner Metab 2017;35:20. https://doi.org/10.1007/s00774-016-0810-7
  30. Fliefel R, Troltzsch M, Kuhnisch J, Ehrenfeld M, Otto S. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg 2015;44:568-585. https://doi.org/10.1016/j.ijom.2015.01.026
  31. Kim KM, Rhee Y, Kwon YD, Kwon TG, Lee JK, Kim DY. Medication related osteonecrosis of the jaw: 2015 position statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons. J Bone Metab 2015;22:151-165. https://doi.org/10.11005/jbm.2015.22.4.151
  32. Rosella D, Papi P, Giardino R, Cicalini E, Piccoli L, Pompa G. Medication-related osteonecrosis of the jaw: clinical and practical guidelines. J Int Soc Prev Community Dent 2016;6:97-104. https://doi.org/10.4103/2231-0762.178742
  33. Agrillo A, Filiaci F, Ramieri V, et al. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): 5 year experience in the treatment of 131 cases with ozone therapy. Eur Rev Med Pharmacol Sci 2012;16:1741-1747.
  34. Kim JW, Kim SJ, Kim MR. Leucocyte-rich and platelet-rich fibrin for the treatment of bisphosphonate-related osteonecrosis of the jaw: a prospective feasibility study. Br J Oral Maxillofac Surg 2014;52:854-859. https://doi.org/10.1016/j.bjoms.2014.07.256
  35. Kwon YD, Kim DY. Role of teriparatide in medication-related osteonecrosis of the jaws (MRONJ). Dent J (Basel) 2016;4:41. https://doi.org/10.3390/dj4040041
  36. Zushi Y, Takaoka K, Tamaoka J, Ueta M, Noguchi K, Kishimoto H. Treatment with teriparatide for advanced bisphosphonate-related osteonecrosis of the jaw around dental implants: a case report. Int J Implant Dent 2017;3:11. https://doi.org/10.1186/s40729-017-0074-6
  37. Wanger G, Gorby Y, El-Naggar MY, et al. Electrically conductive bacterial nanowires in bisphosphonate-related osteonecrosis of the jaw biofilms. Oral Surg Oral Med Oral Pathol Oral Radiol 2013;115:71-78. https://doi.org/10.1016/j.oooo.2012.08.446
  38. Rodriguez-Lozano FJ, Onate-Sanchez RE. Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents. Med Oral Patol Oral Cir Bucal 2016;21:e595-e600.
  39. Hadaya D, Soundia A, Freymiller E, et al. Nonsurgical management of medication-related osteonecrosis of the jaws using local wound care. J Oral Maxillofac Surg 2018;76:2332-2339. https://doi.org/10.1016/j.joms.2018.05.025
  40. Stanton DC, Balasanian E. Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: review of 33 surgical cases. J Oral Maxillofac Surg 2009;67:943-950. https://doi.org/10.1016/j.joms.2008.12.057
  41. Carlson ER, Schlott BJ. Anti-resorptive osteonecrosis of the jaws: facts forgotten, questions answered, lessons learned. Oral Maxillofac Surg Clin North Am 2014;26:171-191. https://doi.org/10.1016/j.coms.2014.01.005
  42. Kyrgidis A, Vahtsevanos K, Koloutsos G, et al. Bisphosphonaterelated osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J Clin Oncol 2008;26:4634-4638. https://doi.org/10.1200/JCO.2008.16.2768
  43. Park H, Copeland C, Henry S, Barbul A. Complex wounds and their management. Surg Clin North Am 2010;90:1181-1194. https://doi.org/10.1016/j.suc.2010.08.001
  44. Yamamoto S, Maeda K, Kouchi I, et al. Development of antiresorptive agent-related osteonecrosis of the jaw after dental implant removal: a case report. J Oral Implantol 2018;44:359-364. https://doi.org/10.1563/aaid-joi-d-18-00032